S. 2068

Summary

S. 2068, the End Prescription Drug Ads Now Act, was introduced in the Senate on Jun 12, 2025 by Sen. Bernard Sanders (I) with 6 co-sponsors. It was referred to Health, Education, Labor, And Pensions, and last saw action on Jun 12, 2025: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Record

Text

S. 2068 has 6 co-sponsors.

119 S2068 IS: End Prescription Drug Ads Now Act
 U.S. Senate
 2025-06-12
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 II  119th CONGRESS  1st Session  S. 2068  IN THE SENATE OF THE UNITED STATES   June 12, 2025   Mr. Sanders  (for himself,  Mr. King ,  Mr. Murphy ,  Mr. Welch ,  Mr. Merkley , and  Mr. Durbin ) introduced the following bill; which was read twice and referred to the  Committee on Health, Education, Labor, and Pensions    A BILL
To ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products.
1.
Short title
This Act may be cited as the   End Prescription Drug Ads Now Act  .
2.
Prohibition on direct-to-consumer drug advertising of drugs
(a)
In general
Section 502 the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352 ) is amended by adding at the end the following:
(hh)
(1)
If it is a drug approved under section 505 or licensed under section 351 of the Public Health Service Act, and subject to section 503(b)(1), and the holder of the approved application under section 505 or of the license under such section 351 has conducted direct-to-consumer advertising of the drug within the most recent 30-day period.
(2)
For purposes of this paragraph, the term  direct-to-consumer advertising , with respect to a drug subject to section 503(b)(1), means any promotional communication targeting consumers, including through television, radio, print media, digital platforms, and social media, for purposes of marketing such a drug.
 .
(b)
Effective date
The amendment made by subsection (a) shall take effect 30 days after the date of enactment of this Act, and shall apply with respect to any drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) or licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ), regardless of when the drug was approved or licensed.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

A bill to ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products.

Sponsors

Sen. Bernard Sanders (I) sponsors S. 2068, and 6 members have co-sponsored it, 5 of them from the day it was introduced.

Bernard Sanders

Sen. · I–VT · Sponsor

Introduced Jun 12, 2025

Richard Durbin

Sen. · D–IL · Co-sponsor

Joined Jun 12, 2025 · Original

Angus King

Sen. · I–ME · Co-sponsor

Joined Jun 12, 2025 · Original

Jeff Merkley

Sen. · D–OR · Co-sponsor

Joined Jun 12, 2025 · Original

Christopher Murphy

Sen. · D–CT · Co-sponsor

Joined Jun 12, 2025 · Original

Peter Welch

Sen. · D–VT · Co-sponsor

Joined Jun 12, 2025 · Original

Tammy Duckworth

Sen. · D–IL · Co-sponsor

Joined Jun 17, 2025

Show 7 of 7 rows

PreviousNext

Committees

S. 2068 went before 1 committee: Health, Education, Labor, and Pensions.

Health, Education, Labor, and Pensions

Health, Education, Labor, and Pensions

Referred To · Jun 12, 2025 · 747 Bills

Actions

S. 2068 has taken 2 actions since Jun 12, 2025.

Votes

S. 2068 has not gone to a roll call.

Related bills

1 bill is related to S. 2068, as Identical bill.

HR 4605End Prescription Drug Ads Now ActJul 22, 2025 · Referred to the House Committee on Energy and Commerce. · Identical bill

Show 1 of 1 row

PreviousNext

Titles

S. 2068 goes by 3 titles, 1 of them short titles.

• End Prescription Drug Ads Now Act — Display Title
• End Prescription Drug Ads Now Act — Short Title(s) as Introduced
• A bill to ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products. — Official Title as Introduced

Lobbying

4 clients hired 4 firms and 115 registered lobbyists who named S. 2068 in 19 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Labor Issues/Antitrust/Workplace, Taxation/Internal Revenue Code, Insurance, Medicare/Medicaid, Aerospace, Automotive Industry, Aviation/Airlines/Airports.

Clients

Who paid to be heard, by how many filings named the bill.

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 115.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

Classification

The Congressional Research Service files S. 2068 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; S. 2068’s is Health.

Source: congress.gov · legiscan.com